Paper28642008
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C and 20 others. Lancet Oncol, 2017. Cited by 485 papers, by iCite.
Cite this record
ConductScience Library. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Papers, record 28642008. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28642008
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Lung Neoplasms | Major topic |
| Small Cell Lung Carcinoma | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Chemoradiotherapy | |
| Cisplatin | |
| Dose Fractionation, Radiation | |
| Esophagitis | |
| Etoposide | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Intention to Treat Analysis | |
| Male | |
| Middle Aged | |
| Neoplasm Staging | |
| Neutropenia | |
| Radiation Pneumonitis | |
| Survival Rate |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 20465 | Cancer Research UK | United Kingdom | PubMed | |
| 8154 | Cancer Research UK | United Kingdom | PubMed |
Source PubMed
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00433563 | Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT04696939 | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | Background | ClinicalTrials.gov | |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT | Background | ClinicalTrials.gov | |
| NCT06529081 | Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer | Background | ClinicalTrials.gov |
Comments and corrections9
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 28642007 | Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer? | https://conductscience.org/library/papers/28642007 | PubMed |
| Comment in | 28971812 | Is it time to convert the frequency of radiotherapy in small-cell lung cancer? | https://conductscience.org/library/papers/28971812 | PubMed |
| Comment in | 28971813 | Is it time to convert the frequency of radiotherapy in small-cell lung cancer? | https://conductscience.org/library/papers/28971813 | PubMed |
| Comment in | 28971814 | Is it time to convert the frequency of radiotherapy in small-cell lung cancer? | https://conductscience.org/library/papers/28971814 | PubMed |
| Comment in | 28971815 | Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply. | https://conductscience.org/library/papers/28971815 | PubMed |
| Comment in | 29143097 | [Concurrent once-daily or twice-daily chemoradiotherapy in limited-stage small-cell lung cancer?] | https://conductscience.org/library/papers/29143097 | PubMed |
| Comment in | 29208381 | CONVERTed or not: what are the barriers to implementing the evidence? | https://conductscience.org/library/papers/29208381 | PubMed |
| Comment in | 29208382 | CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply. | https://conductscience.org/library/papers/29208382 | PubMed |
| Comment in | 29221253 | Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer. | https://conductscience.org/library/papers/29221253 | PubMed |
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15570087 | Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. | J Clin Oncol | 2004 | https://conductscience.org/library/papers/15570087 | PubMed |
| 2 | 8622028 | Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. | J Clin Oncol | 1996 | https://conductscience.org/library/papers/8622028 | PubMed |
| 3 | 15561810 | A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. | Oncologist | 2004 | https://conductscience.org/library/papers/15561810 | PubMed |
| 4 | 19652623 | The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. | J Thorac Oncol | 2009 | https://conductscience.org/library/papers/19652623 | PubMed |
| 5 | 8381164 | Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. | J Clin Oncol | 1993 | https://conductscience.org/library/papers/8381164 | PubMed |
| 6 | 17008692 | Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/17008692 | PubMed |
| 7 | 1331787 | A meta-analysis of thoracic radiotherapy for small-cell lung cancer. | N Engl J Med | 1992 | https://conductscience.org/library/papers/1331787 | PubMed |
| 8 | 7165009 | Toxicity and response criteria of the Eastern Cooperative Oncology Group. | Am J Clin Oncol | 1982 | https://conductscience.org/library/papers/7165009 | PubMed |
| 9 | 15674960 | Early versus late chest radiotherapy for limited stage small cell lung cancer. | Cochrane Database Syst Rev | 2005 | https://conductscience.org/library/papers/15674960 | PubMed |
| 10 | 9817271 | Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. | J Clin Oncol | 1998 | https://conductscience.org/library/papers/9817271 | PubMed |
| 11 | 23649448 | Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. | Chest | 2013 | https://conductscience.org/library/papers/23649448 | PubMed |
| 12 | 4580860 | Keynote address on biostatistics and data retrieval. | Cancer Chemother Rep 3 | 1973 | https://conductscience.org/library/papers/4580860 | PubMed |
| 13 | 16344277 | Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. | Ann Oncol | 2006 | https://conductscience.org/library/papers/16344277 | PubMed |
| 14 | 23273996 | Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. | Int J Radiat Oncol Biol Phys | 2013 | https://conductscience.org/library/papers/23273996 | PubMed |
| 15 | 9920950 | Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. | N Engl J Med | 1999 | https://conductscience.org/library/papers/9920950 | PubMed |
| 16 | 26792218 | Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. | BMJ Open | 2016 | https://conductscience.org/library/papers/26792218 | PubMed |
| 17 | 12654444 | Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. | Int J Radiat Oncol Biol Phys | 2003 | https://conductscience.org/library/papers/12654444 | PubMed |
| 18 | 1316951 | Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. | J Clin Oncol | 1992 | https://conductscience.org/library/papers/1316951 | PubMed |
| 19 | 27436850 | Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. | Ann Oncol | 2016 | https://conductscience.org/library/papers/27436850 | PubMed |
| 20 | 16505424 | Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16505424 | PubMed |
Cited by296
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 485 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42907122 | Adebrelimab combined with apatinib and chemotherapy for neoadjuvant therapy and biomarker analysis in limited-stage small cell lung cancer: study protocol for a single-arm trial. | BMJ Open | 2026 | https://conductscience.org/library/papers/42907122 | PubMed |
| 42889196 | Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42889196 | PubMed |
| 42840183 | The Five-Decade Journey of Small Cell Lung Cancer. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/42840183 | PubMed |
| 42824004 | Romiplostim for refractory chemotherapy-induced thrombocytopenia in a long-term survivor of limited-stage small cell lung cancer: a case report. | Front Oncol | 2026 | https://conductscience.org/library/papers/42824004 | PubMed |
| 42823088 | Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A). | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42823088 | PubMed |
| 42812441 | Impact of ALC Nadir and EDRIC on survival outcomes in limited-stage small cell lung cancer receiving chemoradiotherapy: a retrospective analysis comparing twice-daily and once-daily radiotherapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42812441 | PubMed |
| 42698800 | Neoadjuvant PD-1 Blockade Tislelizumab (BGB-A317) in Combination With Etoposide and Platinum-Based Chemotherapy for Limited-Disease Small Cell Lung Cancer. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42698800 | PubMed |
| 42643276 | ONC201 enhances the radiosensitivity of small-cell lung cancer via inhibition of the FAK signaling pathway. | iScience | 2026 | https://conductscience.org/library/papers/42643276 | PubMed |
| 42591674 | Consolidative thoracic radiotherapy following first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: A systematic review and meta-analysis. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42591674 | PubMed |
| 42583201 | Dose-escalated twice daily radiotherapy for limited stage small cell lung cancer: an implementation strategy in the Netherlands. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42583201 | PubMed |
| 42582865 | Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42582865 | PubMed |
| 42568026 | Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation. | Drugs | 2026 | https://conductscience.org/library/papers/42568026 | PubMed |
| 42558713 | Efficacy and safety of immunotherapy combined with chemoradiotherapy in limited-stage small cell lung cancer: a systematic evaluation and meta-analysis of randomized controlled trials. | Front Immunol | 2026 | https://conductscience.org/library/papers/42558713 | PubMed |
| 42557939 | Chemotherapy and Radiotherapy Regimens for Limited-Stage Small Cell Lung Cancer Treated With Accelerated Hyperfractionated Radiotherapy Combined With Chemotherapy: A Real-World Study. | Cancer Med | 2026 | https://conductscience.org/library/papers/42557939 | PubMed |
| 42529258 | Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis. | JTO Clin Res Rep | 2026 | https://conductscience.org/library/papers/42529258 | PubMed |
| 42364037 | Impact of weight loss on adverse events during chemoradiotherapy in patients with small cell lung cancer: a retrospective study. | Support Care Cancer | 2026 | https://conductscience.org/library/papers/42364037 | PubMed |
| 42337559 | A risk-adapted, dose-optimized esophagus-sparing radiation therapy technique for high-risk patients with lung cancer: feasibility, dosimetry, and acute esophageal toxicity. | Radiat Oncol | 2026 | https://conductscience.org/library/papers/42337559 | PubMed |
| 42306666 | Surgery versus radiotherapy after neoadjuvant immunochemotherapy in limited-stage small cell lung cancer. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42306666 | PubMed |
| 42303122 | Prophylactic Versus Therapeutic Sucralfate in Patients at High Risk for Radiation Esophagitis: Randomized Controlled Trial. | Pract Radiat Oncol | 2026 | https://conductscience.org/library/papers/42303122 | PubMed |
| 42279364 | Review of Management of Clinical Stage I Small Cell Lung Cancer: The Rising Role of Surgical Resection. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279364 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28642008
GET https://conductscience.org/api/papers/v1/28642008/authors?page=2